Column List | SMC Laboratories Inc.

2025.02.06

[CAIA research seen in an example study] Custom model service for realizing a wide range of research

In recent years, we have received many requests about our services, starting from the establishment of pathological models, in response to the increasing diversity of diseases and the needs for therapeutic drug development. Therefore, today we would like to introduce an example study regarding custom model services, for which we have received many inquiries….

2025.02.05

[Case Study] Why do disease model mice change the outcomes?

If you are considering using a lung fibrosis model in a drug efficacy study, you can maximize the efficacy of your compound by using a disease induction model that is appropriate for your evaluation, rather than using a standard pathological model. In this article, we will provide a clear overview of the disease induction…

2025.02.04

Infliximab (TNF-a antibody) data in IBD model

We introduce some of the data, the results for Infliximab (TNF-a antibody), from the full version of the IBD model materials. Infliximab (TNF-a antibody) shows the improvement in the fibrosis area compared to the DSS group. For more detailed data, please contact us using the form below.

2025.02.04

Latest IBD Models Materials

We are pleased to introduce the latest materials showcasing our DSS induced IBD model, designed to provide valuable insights for your pre-clinical research. You can download the digest version here: (This version includes an overview of the model and an approval drug data) The Full version includes the following content. ・Chronic DSS model…

2025.02.04

Preclinical COPD research with positive controls

We would like to introduce a positive control (Roflumilast) in a drug efficacy evaluation study using PPE-induced COPD model. Our clients previously asked, “Do you have a positive control for COPD trials?” and we have now acquired the data and launched the product. The drug used as a positive control is roflumilast, a PDE-4…

2025.02.03

TAA model: Acute liver failure model

We would like to introduce an acute liver failure (ALF), thioacetamide (TAA)-induced ALF model. For this model, major endpoints in pharmacology studies include histological assessment of hepatic injury and blood biochemistry (ALT and AST). The TAA model is as widely used as ALF model and characterized by hepatocellular necrosis caused by an active metabolite…

2025.02.03

The comparison of NASH-HCC and other HCC models

Today, we present the third part of the comparison table on liver cancer models. Liver cancer is the sixth most common cancer in the world and the third most common cause of cancer-related death in 2020. Among them, hepatocellular carcinoma (HCC) is known to account for about 90% of all liver cancers. Hepatitis B…

2025.02.03

The STAM model as a model of liver fibrosis

Today, we present the comparison table on fibrosis models of the liver. Liver fibrosis is defined as excessive extracellular matrix deposition preceded by chronic liver injury, which can progress to liver failure. The factors that can cause liver fibrosis include oxidative stress, cholestasis, and NASH. Therefore, when assessing the efficacy of anti-fibrotic compounds, it…

2025.02.03

Silica-induced pulmonary fibrosis model

We would like to introduce you to a Silica-induced pulmonary fibrosis model. This model is suitable for you if you want to evaluate lung fibrosis over a long period of time (e.g. cell therapy) The Silica-induced pulmonary fibrosis model reproduces the pathology of the Silicosis, with the production of reactive oxygen species, cell death…

2025.02.03

In Vitro Assay Service for Fibrosis Evaluation

We are delighted to announce the launch of our new in vitro assay service for fibrosis evaluation. By launching this service, we now offer a cost-effective and efficient way to conduct preliminary studies and screen compounds for potential fibrotic effects, saving valuable time and resources in your drug development journey. This not only…